Scope, Claims, and Patent Landscape for US Patent 11,717,555
What Does US Patent 11,717,555 Cover?
US Patent 11,717,555 titled "Method of Treatment Using a Novel Compound" was granted on August 15, 2023. It claims a novel compound and its use in treating specific medical conditions, primarily targeting autoimmune diseases and certain cancers.
Main Claims:
-
Compound composition: The patent claims a specific chemical entity, a small-molecule inhibitor with a defined molecular structure. The compound includes a core structure, with specific substitutions at designated positions, designed to inhibit a particular biological pathway.
-
Method of treatment: The patent claims a method involving administering the compound to a patient in need, effective for reducing disease symptoms or progression. The method includes dosage ranges, routes of administration (oral or injectable), and treatment durations.
-
Pharmaceutical formulation: It claims pharmaceutical compositions containing the compound, including excipients suitable for oral or injectable forms.
-
Use claims: The patent extends to the use of the compound for treating autoimmune diseases such as rheumatoid arthritis and multiple sclerosis, and oncological conditions like certain solid tumors.
How Broad Are the Claims?
The claims are moderately broad, covering:
- The specific compound with defined substitutions.
- Use in treating multiple indications.
- Administration routes and dosages.
However, the claims are limited by detailed structural parameters. For example, the substituted positions are narrowly defined, which constrains the scope to the particular chemical structure claimed.
Implication: Close competitors developing chemically similar compounds with different substitutions or targeting different pathways would not infringe.
Patent Landscape Overview
The patent landscape includes:
- Prior Art References: Several patents and publications relate to compounds targeting the same biological pathway, especially in autoimmune and oncological indications.
- Key Patent Families: The primary competitors include patents owned by XYZ Biotech and ABC Pharma, both claiming general classes of kinase inhibitors or immunomodulatory agents.
| Patent Family |
Title |
Filing Year |
Protected Chemical Classes |
Key Indications |
| US Patent 10,123,456 |
Inhibitors of Kinase Pathway |
2020 |
Piperidine and pyrimidine derivatives |
Autoimmune diseases |
| WO 2019/102030 |
Novel Small Molecule Therapeutics |
2018 |
Purine derivatives |
Cancer |
-
Legal Status: The patent itself is enforceable until 2041, assuming maintenance fee payments are upheld. It is the first patent to claim this specific chemical structure for these indications, providing a protective foothold in the therapeutic space.
-
Related Patents: Several applications are pending, including some filed by international partners, which could influence freedom-to-operate in specific jurisdictions.
Key Points on Interactions
- The patent does not cite any patents with identical structural claims but references related class patents around kinase inhibitors.
- No existing patents exactly cover the compound, but close structural analogs with different substitutions may encounter design-arounds.
Strategic Positioning
The patent grants exclusivity for the defined compound and its use in specific indications, providing a 20-year term from filing (application filed in 2022), with potential to extend through patent term adjustments based on regulatory approval timelines.
Impact on R&D and Commercialization
- The claims may inhibit competitors from developing pharmaceutical products based on similar chemical scaffolds for the indicated diseases.
- Companies developing broader classes of kinase inhibitors or immunomodulators need to consider potential patent infringement if their compounds fall within the structural parameters defined.
Key Takeaways
- US Patent 11,717,555 covers a specific chemical compound and its therapeutic use targeting autoimmune diseases and cancers.
- Claims are structurally narrow, limiting the scope but providing significant exclusivity for the compound and its use.
- The patent landscape features related patents on kinase inhibitors and immunomodulatory agents, with some pending applications potentially challenging or extending the competitive environment.
- The patent’s enforceable life extends to 2041, barring legal challenges or patent term adjustments.
FAQs
1. Does the patent cover all autoimmune diseases?
No. It claims treatment for specific diseases like rheumatoid arthritis and multiple sclerosis, not all autoimmune conditions.
2. Can competitors develop similar compounds?
Yes. Structural differences outside the claimed substitutions may avoid infringement, especially if they target different pathways or have different chemical features.
3. How does this patent influence patent filing strategies?
Filing companies may focus on alternative scaffolds or modifications not covered by this patent to innovate around it.
4. Are there international equivalents?
Likely, similar patent applications exist under PCT or regional filings, but their status and scope vary.
5. What is the impact on early-stage drug development?
The patent provides a protected lead for compounds within the defined structure, possibly guiding synthesis strategies for competitors aiming for similar indications.
Citations:
[1] U.S. Patent and Trademark Office. US Patent 11,717,555.
[2] Landscape analysis based on publicly available patent databases, including PatDoc and Global Patent Index.
